Clinical trials: Lassa Fever, active
Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
This study aim to validate the clinical performances of two newly developed isothermal nucleic acid amplification bioassays modules for EBOV and LASV.
- Trial name
- NCT07681752
- Testing
- FORTIFIEDx and DECIPHER bioassays
- Volunteers
- 150 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Lassa Fever
LAssa Fever Adjunct Treatment With DEXamethasone
Dexamethasone is a corticosteroid which can modulate inflammatory-mediated tissue damage associated with a wide range of infectious diseases.
- Trial name
- LADEX (NCT06222723)
- Testing
- Dexamethasone, Ribavirin
- Where
- Nigeria
- Volunteers
- 42 people
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Lassa Fever
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Lassa fever is an acute viral disease belonging to the category of viral hemorrhagic fevers. It is endemic in West Africa. Outbreaks occur every year, and it is estimated that between 100 000 and 300 000 individuals are infected…
- Trial name
- FIRST-IN-MOP (NCT07833436)
- Testing
- Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Lassa Fever
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
- Trial name
- NCT05868733
- Testing
- Day 1 Dose (2×106 pfu), Day 1 Dose (1×107 pfu), Day 1 Dose (2×10^5 pfu)
- Where
- 3 sites in Ghana, Liberia and 1 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Lassa Fever
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%.
- Trial name
- NCT06212336
- Testing
- Favipiravir, Ribavirin, Dexamethasone
- Where
- 4 sites in Liberia, Nigeria
- Volunteers
- 1,755 people
- Sponsor
- Irrua Specialist Teaching Hospital
Lassa Fever, Lassa Virus Infection
Lassa Fever Clinical Course and Prognostic Factors in Nigeria
The investigators propose to conduct a nationwide (Nigeria), prospective, non-interventional cohort study describing the clinical course, biological characteristics, case management and outcomes in patients hospitalized for a…
- Conditions
- Lassa Fever, Lassa Virus Infection, Pregnancy Complications, Acute Kidney Injury
- Trial name
- LASCOPE (NCT03655561)
- Testing
- Non interventional research
- Where
- 2 sites in Nigeria
- Volunteers
- 1,200 people
- Sponsor
- Alliance for International Medical Action